Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
Halberd Corporation (OTC: HALB) said it is continuing collaboration with Mississippi State University scientists and is pursuing a U.S. government contract in Q4 2025 to finance advanced animal research on a multi-part nasal spray intended as an early post-head-trauma treatment for traumatic brain injury (TBI).
Halberd reported prior Phase-1 animal testing showed reduced brain markers of TBI damage, plans Phase-2 animal tests using AI after its recent acquisition of NeuroSense AI, and noted potential military benefits such as expedited return-to-duty. The company is also pursuing private investment and possible corporate restructuring.
Halberd Corporation (OTC: HALB) ha detto di continuare la collaborazione con gli scienziati della Mississippi State University e di perseguire un contratto governativo statunitense nel quarto trimestre del 2025 per finanziare ricerche avanzate sugli animali su uno spray nasale multi-componente previsto come trattamento precoce dopo trauma cranico per lesione cerebrale traumatica (TBI).
Halberd ha riferito che i test su animali di fase 1 precedenti hanno mostrato una riduzione dei marker cerebrali del danno da TBI, pianifica test su animali di fase 2 utilizzando l'IA dopo l'acquisizione recente di NeuroSense AI, e ha indicato potenziali benefici militari come un ritorno al servizio accelerato. L'azienda sta anche perseguendo investimenti privati e una possibile ristrutturazione aziendale.
Halberd Corporation (OTC: HALB) dijo que continúa la colaboración con científicos de la Mississippi State University y que busca un contrato gubernamental de Estados Unidos en el cuarto trimestre de 2025 para financiar investigación avanzada con animales sobre un spray nasal multi-componente previsto como tratamiento temprano tras un trauma craneoencefálico para lesión cerebral traumática (TBI).
Halberd informó que las pruebas en animales de la fase 1 anteriores mostraron reducción de marcadores cerebrales del daño por TBI, planifica pruebas en animales de fase 2 utilizando IA tras la reciente adquisición de NeuroSense AI, y señaló beneficios militares potenciales como una pronta reincorporación al servicio. La empresa también busca inversión privada y una posible reestructuración corporativa.
Halberd Corporation (OTC: HALB)은 미시시피 주립대 과학자들과의 협력을 계속하고 있으며 2025년 4분기에 미국 정부 계약을 추진해 외상성 뇌손상(TBI)을 조기에 치료하기 위한 다성분 비강 스프레이에 대한 고급 동물 연구를 재정 지원할 것이라고 밝혔다.
Halberd는 이전 1상 동물 시험에서 TBI 손상에 대한 뇌 표지지표가 감소했음을 보여주었고, 최근 NeuroSense AI를 인수한 후 AI를 활용한 2상 동물 시험 계획을 세웠으며, 조기 복무 복귀와 같은 잠재적 군사 이점도 지적했다. 또한 회사는 민간 투자 및 가능한 기업 구조조정도 추진 중이다.
Halberd Corporation (OTC: HALB) a indiqué qu'elle poursuit sa collaboration avec les scientifiques de l'Université d'État du Mississippi et qu'elle vise un contrat gouvernemental américain au 4e trimestre 2025 pour financer des recherches avancées sur les animaux concernant un spray nasal multi-composants destiné à un traitement précoce après trauma crânien pour une lésion cérébrale traumatique (TBI).
Halberd a annoncé que les tests animaux de phase 1 antérieurs ont montré une réduction des marqueurs cérébraux des dommages liés à la TBI, prévoit des tests sur animaux de phase 2 utilisant l'IA après l'acquisition récente de NeuroSense AI, et a noté des bénéfices militaires potentiels tels qu'un retour au service accéléré. L'entreprise recherche également des investissements privés et une éventuelle restructuration d'entreprise.
Halberd Corporation (OTC: HALB) erklärte, dass sie die Zusammenarbeit mit Wissenschaftlern der Mississippi State University fortsetzt und einen US-Regierungsvertrag im vierten Quartal 2025 anstrebt, um fortschrittliche Tierversuche zu einer mehrteiligen nasalen Sprühlösung zu finanzieren, die als frühzeitige Behandlung nach Kopfverletzungen bei traumatischen Hirnverletzungen (TBI) vorgesehen ist.
Halberd berichtete, dass frühere Phase-1-Tierstudien reduzierte Gehirnmarker des TBI-Schadens zeigten, plant Phase-2-Tieruntersuchungen unter Einsatz von KI nach dem jüngsten Erwerb von NeuroSense AI, und hob potenzielle militärische Vorteile wie eine beschleunigte Rückkehr in den Dienst hervor. Das Unternehmen verfolgt auch private Investitionen und eine mögliche Umstrukturierung des Unternehmens.
Halberd Corporation (OTC: HALB) قالت إنها ستستمر في التعاون مع علماء جامعة ولاية ميسيسيبي وتسعى للحصول على عقد حكومي أمريكي في الربع الرابع من عام 2025 لتمويل بحث حيواني متقدم على بخاخ أنفي متعدد المكونات يهدف كعلاج مبكر بعد إصابة الرأس عند الإصابة الدماغية الناتجة عن الصدمة (TBI).
أفادت Halberd بأن اختبارات الحيوان من المرحلة-1 السابقة أظهرت تقليل علامات الدماغ للأذى المرتبط بـ TBI، وتخطط لاختبارات حيوانية من المرحلة-2 باستخدام الذكاء الاصطناعي بعد الاستحواذ الأخير على NeuroSense AI، وأشارت إلى فوائد عسكرية محتملة مثل عودة أسرع للخدمة. كما تسعى الشركة لجذب استثمارات خاصة وإعادة هيكلة محتملة للشركة.
- Phase-1 animal tests showed reduced TBI damage markers
- Completed acquisition of NeuroSense AI to support AI-driven Phase-2 analysis
- Developed a nasal spray designed for immediate post-trauma use
- No government contract awarded yet; funding is being sought in Q4 2025
- Phase-3 tests and human trials have not been planned
- Outcome and timing of private investment or restructuring are uncertain
JACKSON CENTER, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI).
The United States military, for example, has historically experienced rates of suicide among both active duty and veteran groups reaching as high as one per hour. Head trauma associated with contact sports, falls, and automobile accidents has been associated with an increased risk of developing Alzheimer's Disease, Parkinson's Disease, and Epilepsy. The Halberd treatment is a simple multi-part nasal spray that can be first implemented immediately following head trauma and then continued during the initial stages of recovery. This early intervention allows for the effective mitigation of the negative effects associated with TBI.
The government contract that is sought will be used to finance pre-planned, advanced Phase-2 animal research that is designed to determine the efficacy of the nasal spray to reduce the level of biochemical changes and behavioral deficits that can be induced by different levels of TBI that originate from different sources (blasts and impacts). This work is based on previous simpler Phase-1 testing that demonstrated a reduction in the level of markers of TBI-induced damage in the brains of animals that received the nasal spray as compared to those that did not.
The Phase-2 tests will employ the Artificial Intelligence capabilities afforded by Halberd's recent acquisition of NeuroSense AI. Phase-3 tests have not yet been planned, but could involve larger animals and/or preliminary human trials.
A potential advantage of the Halberd nasal spray to the military is an expedited return-to-duty following head trauma or elevated anxiety conditions. This could be a very important aspect of the proprietary Halberd nasal spray to the military.
Halberd is also pursuing private investment and possible corporate restructuring, and will provide pertinent timely updates in future press releases.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
X:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM)
Established in 1974, the Mississippi State University College of Veterinary Medicine (MSU CVM) comprises six locations, catering to all 82 counties in Mississippi and the broader Southeastern United States. The primary campus, situated in Starkville, encompasses the Wise Center, home to the main teaching hospital known as the Animal Health Center. The faculty and staff of the MSU CVM Department of Comparative Biomedical Sciences cover fundamental scientific disciplines essential for veterinary education. MSU CVM is dedicated to an ethical approach in the treatment of animals, demonstrating a sincere passion and commitment.
About NeuroSense AI
NeuroSense AI is a behavioral intelligence platform in development by Halberd Corporation, designed to transform preclinical TBI research through multi-modal behavioral analysis and advanced AI interpretation. The platform combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered pattern recognition to provide objective, continuous assessment of neurological function and recovery. For more information, visit NeuroSenseAI.ai
About Halberd Corporation.
Halberd Corporation (OTC: HALB) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company's portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation's business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
FAQ
What is Halberd (HALB) seeking from the U.S. government in Q4 2025?
What evidence did Halberd cite about the HALB nasal spray's efficacy?
How will NeuroSense AI affect Halberd's planned Phase-2 tests for HALB?
Does Halberd (HALB) plan human trials for the TBI nasal spray?
What potential benefit did Halberd cite for the military from the HALB nasal spray?
